Day-one subcutaneous Leqembi lets eligible people with early Alzheimer's start treatment at home in 2026. Adult children may need to revisit who gives the shots, how safety monitoring fits family schedules, and how coverage works. Leqembi is lecanemab-irmb, a drug that targets amyloid-beta buildup in the brain.
The Eisai and Biogen announcement says the FDA approved the once-weekly at-home starting dose on July 13, 2026, the first at-home starting dose Eisai and Biogen announcement. The launch notice from BioArctic and Eisai dates U.S. availability to August 24, 2026, dispensed for at-home use by patients or caregivers BioArctic and Eisai launch notice.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Does your parent still qualify?
- What does the home start ask of family?
- Which safety monitoring stays in place?
- What changes after 18 months, and what will it cost?
Does your parent still qualify?
Treatment is only for adults with mild cognitive impairment or mild dementia due to Alzheimer's with confirmed amyloid-beta pathology. CMS coverage rules state the same early-stage limit.
If memory or daily function has declined past mild dementia, ask the clinic whether eligibility still holds. Bring the latest cognitive test, amyloid result, and diagnosis letter to the visit. If amyloid confirmation is missing or old, ask what retesting the clinic requires.
What does the home start ask of family?
The Eisai and Biogen announcement describes initiation as 500 mg once weekly as two back-to-back 250 mg autoinjector shots of about 15 seconds each. Patients may start with IV or subcutaneous dosing and switch routes. Home use still needs training and clinician oversight, according to the August 2026 Medscape summary.
Revisit who is available each week and whether travel or work schedules allow steady help. If treatment already began by infusion, ask whether switching to shots makes sense or staying on infusions is simpler. Base the choice on vein access, clinic distance, comfort with shots, and supervision needs.
- who learns the device steps and gives both shots on dose day
- how the family records doses and contacts the clinic with concerns
- whether a backup caregiver can cover illness or travel
Which safety monitoring stays in place?
Labeling carries a boxed warning for amyloid-related imaging abnormalities, swelling called ARIA-E and bleeding-related changes called ARIA-H, according to the FDA July 2026 notice. People with two copies of ApoE ε4, called homozygotes, face higher incidence, so genotype testing should come first.
At-home dosing does not remove safety oversight. A baseline brain MRI plus scheduled follow-up MRIs for ARIA remain required regardless of route. Caregiver training and clinician supervision also stay required, as the August 2026 Medscape report notes.
What changes after 18 months, and what will it cost?
After 18 months of IV or subcutaneous treatment, maintenance is 360 mg subcutaneously once weekly. Subcutaneous maintenance was first approved August 29, 2025, according to the Eisai and Biogen announcement and approval history. Medicare Part B covers Leqembi only when the prescriber joins a CMS registry under coverage with evidence development.
The CMS statement ties broader coverage to registry participation, and listed price summaries cite about $26,500 per year with large 20% coinsurance. Coverage of the new subcutaneous initiation dose was not specifically announced. Ask the clinic whether it participates in the registry and what supplemental coverage would pay before setting a start date.
You Might Also Like
- Serious Illness and End-of-Life Dementia Research Priorities in 2026: A Source-Checked Briefing for Adult Children
- The $100 Million PROTECT-Cog Alzheimer’s Study Announced in 2026: Research Participation Questions for Spouses and Partners
- Tauklarify Tau PET vs Alzheimer’s Blood Tests in 2026: Result Interpretation Questions for Memory Clinic Patients
